Hair composition

An oral or topical composition comprising a nuclear factor erythroid-2 related factor 2 agonist and a liver X receptor agonist, wherein the amounts of each of the nuclear factor erythroid-2 related factor 2 agonist and the liver X receptor agonist produce a synergistic induction of the antioxidant response element and/or up-regulation of hemoxygenase 1 in HaCaT immortalised human keratinocyte cells and/or up-regulation of NAD(P)H dehydrogenase (quinone) 1 in human hair follicle cells,

• wherein the oral or topical composition comprises ≦9, preferably ≦8% w/w β-sitosterol,
• wherein when the oral or topical composition comprises a catechin, the oral or topical composition comprises 0.001 to 90, preferably 0.005 to 70, most preferably 0.01 to 50% w/w catechins,
• wherein the oral or topical composition excludes pregnenolone, 4, 5-dihydrofuranodiene-6-one, epoxy santamarin, hydroquinone, longistyline, monacolin K, protoanemonin, N-(2,2,2-trifluoro-ethyl)-N-[4-(2,2,2-tri-fluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide, dihydronepetalactone, iridomyrmecin, and dihydroactinidiolide,
• wherein when the oral or topical composition comprises guggelsterone to epigallocatechin gallate, the oral or topical composition excludes a guggelsterone to epigallocatechin gallate weight ratio of 1 to 28, and
• wherein when the oral or topical composition comprises sodium dilauramide glutamide lysine, the oral or topical composition excludes 0.3% w/w sodium dilauramide glutamide lysine.

An oral or topical composition comprising a nuclear factor erythroid-2 related factor 2 agonist and a liver X receptor agonist which agonists, in combination in the composition, exert a synergistic effect on the induction of the antioxidant response element (“ARE”),

• wherein the oral or topical composition comprises ≦9, preferably ≦8% w/w β-sitosterol,
• wherein when the oral or topical composition comprises a catechin, the oral or topical composition comprises 0.001 to 90, preferably 0.005 to 70, most preferably 0.01 to 50% w/w catechins;
• wherein the oral or topical composition excludes pregnenolone, 4, 5-dihydrofuranodiene-6-one, epoxy santamarin, hydroquinone, longistyline, monacolin K, protoanemonin, N-2,2,2-trifluoro-ethyl)-N[4-(2,2,2-tri-fluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide, dihydronepetalactone, iridomyrmecin, and dihydroactinidiolide;
• and wherein when the oral or optical composition comprises guggelsterone and epigallocatechin gallate, the oral or topical composition excludes a guggelsterone to epigallocatechin gallate weight ratio of 1 to 28;
• and
• wherein when the oral or topical composition comprises sodium dilauramide glutamide lysine, the oral or topical composition excludes 0.3% w/w sodium dilauramide glutamide lysine;
• wherein the concentration of nuclear factor erythroid-2 related factor 2 agonist in the composition is at least 0.09 w/w %, preferably in the range 0.1-49 w/w or 0.1-49 w/v %, more preferably in the range 0.2-250 w/w % or w/v %;
• and
• wherein the concentration of the liver X receptor agonist in the composition is at least 0.09 w/w % or 0.09 w/v %, preferably in the range 0.1-49 w/w % or 0.1-49 w/v % more preferably in the range 0.2-25 w/w % or w/v %.